MBX Biosciences, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
MBX$54.06+5.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
(a) None.
(b) Trading Plans
During the three months ended December 31, 2025, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated any Rule 10b5-1 trading arrangements (as defined in Item 408(a) of Regulation S-K), except as follows:
| Name | Title | Reporting Action | Plan Start Date | Plan End Date | Maximum number of Shares of Common Stock to be Sold | Intended to Satisfy Rule 10b5-1(c)? |
|---|---|---|---|---|---|---|
| Richard Bartram | Chief Financial Officer | Plan Adoption | December 19, 2025 | March 15, 2027 | 121,485 | Yes |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.